SpringerLink
Log in

Design and Evaluation of Sustained Release Bilayer Tablets of Oxcarbazepine

  • Original Article
  • Published:
Journal of Pharmaceutical Innovation Aims and scope Submit manuscript

Abstract

Objective

The aim of the present study is to modify the release profile of oxcarbazepine by formulating it as a bilayer tablet using direct compression method with dual compression.

Methods

In the bilayer system, the immediate release layer was formulated using four types of disintegrants, sodium starch glycolate (SSG), croscarmellose sodium (CCS), cross-linked polyvinylpyrrollidone (crospovidone), and starch. It was found that immediate release layer containing sodium starch glycolate gave faster disintegration time. Therefore, sodium starch glycolate was utilized in the preparation of bilayer tablets in this study. The sustained release layer was prepared utilizing three hydrophobic polymers, two of them are acrylics (Eudragit RS®, Eudragit RL®) and the third one is ethyl cellulose. The prepared bilayer tablets were evaluated for hardness, friability, weight variation, content uniformity, and dissolution profile.

Results

The results showed that combination of Eudragit RL® with Eudragit RS® in ratio of 2:1 gave the best modified release profile. Also, using di calcium phosphate as a binder and microcrystalline cellulose (Avicel PH 101) as a diluent resulted in a slower release profile comparing with other formulas. Based on the ʄ2 similarity factor value comparing with reference standard curve, F15, which contains Eudragit RL® and RS® in ratio of 2:1 with mannitol as a diluent and Avicel 102 as a binder, was selected as the best optimized formula. Drug release followed diffusion mechanism rather than erosion mechanism. Furthermore, FTIR spectra showed no possibility of chemical interaction between the drug and polymers, which were used in preparation of bilayer tablet. Stability studies of bilayer tablets under accelerated conditions indicated that the shelf life of the prepared tablets was 3 years and 5 months at 25 °C. However, stability of optimized formula in day light at room temperature revealed that the shelf life of oxcarbazepine is 1 year and 9 months.

Conclusion

The results of this study clearly demonstrate that oxcarbazepine can be successfully prepared as a bilayer modified release tablet.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12
Fig. 13
Fig. 14
Fig. 15
Fig. 16
Fig. 17
Fig. 18
Fig. 19
Fig. 20
Fig. 21

Similar content being viewed by others

References

  1. Vyas SP, Khar RK. Controlled drug delivery concepts and advances. vallabh prakashan 2002; 1: 411–47.

  2. Roni MA, Kibria G, Jalil R. Formulation and in vitro evaluation of alfuzosin extended-release tablet using directly compressible Eudragit. Ind J Pharm Sci. 2009;71(3):252–8.

    Article  CAS  Google Scholar 

  3. Makhija SN, Vavia PR. Once daily sustained release tablets of venalafaxine, a novel antidepressant. Eur J Pharm Biopharm. 2002;54:9–15.

    Article  CAS  PubMed  Google Scholar 

  4. Kamble S, Poul B, Udapurkar P. Bilayer tablet of tramadol and gabapentine for combination pharmacotherapy of neuropathic pain: development and characterization. Int J App Pharm. 2018;10(3):100–7.

    Article  CAS  Google Scholar 

  5. Sheetal M, Supriya S, Kadam V. Formulation, and evaluation of oxcarbazepine fast dissolve tablets. 2007;69(2):211–4.

    Google Scholar 

  6. Lloyd P, Flesch G, Dieterle. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994;35(suppl 3): S10-S13.

  7. Michael JM. Oxcarbazepine: mechanisms of action. In: Rene HL, Brain SM, Richard HM, Emilio P, editors. Antiepileptic Drugs. 5th ed. USA: Lippincott williams & wilking; 2002. p. 451–8.

    Google Scholar 

  8. Anupama K, Shelly K, Neena B. Formulation, and evaluation of mouth dissolving tablets of oxycarbazepine. Int J of Pharmacy and Pharma Sci. 2009;1(suppl 1):12–23.

    Google Scholar 

  9. Nirva VP, Narendra PC, Mayur PP. Formulation design of oxcarbazepine fast release tablets prepared by melt granulation technique. Asian J of Pharm 2008;2: 22–26.

  10. Higuchi T, Connors KA. Phase solubility techniques. Advanced Analytical Chemistry of Instrumentation. 1965;4:117–212.

    CAS  Google Scholar 

  11. Rawlins EA. Bentleys textbook of pharmaceutics. 8th wd. U.K.: Bailliere Tindall 2006;641–649.

  12. Biritish Pharmacopeia (BP). Electronic edition. London: Crown, Inc. 2007.

  13. Odeku OA. Tablet Evaluation Tests.Pharmadepia 2008.

  14. Paulo E, Renata O, Gerson P. Oxcarbazepine: validation and application of an analytical method Braz J Pharm Sci 2010; 46(2): 256–71.

  15. Nirav P, Narendra C, Jayvadan P, Tejal S, Julan D, Rajnikant P. Comparison of in vitro dissolution profiles of oxcarbazepine-HP B-CD tablets formulations with marketed oxcarbazepine tablets. Dissolut Technol. 2008;15:28–34.

    Article  Google Scholar 

  16. Naringreker GV, Arnold KA, Erkaboni D. Controlled-release formulations, method of manufacture, and use thereof, United States Patent 12/330280,2008.

  17. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanism of solute release from porous hydrophilic polymer. Int J Pharm. 1983;15:25–35.

    Article  CAS  Google Scholar 

  18. Atul K, Ashok KT, Narendra KJ, Subheet J. Formulation, and in vitro evaluation of extended-release matrix tablets of zidovudine: influence of combination of hydrophilic and hydrophobic matrix formers. AAPS Pharm SciTech 2006; 7(1) Article 1: E1-E9.

  19. Nahla SB, Ibrahim ME, Alanood SA. Controlled-release carbamazepine matrix granules and tablets compressing lipophilic and hydrophilic components. Drug Deliv. 2009;16(1):57–65.

    Article  Google Scholar 

  20. Al-Taani BM, Tashtoush BM. Effect of microenvironment pH of swellable and erodible buffered matrices on the release characteristics of diclofenac sodium. AAPS Pharm Sci Tech. 2003;4:E43.

    Article  Google Scholar 

  21. Mohan A, Sangeetha G. In vitro-in vivo evaluation of fast-dissolving tablets containing solid dispersion of oxcarbazepine. Int J Pharm Pharm Sci. 2016;8(8):124–31.

    CAS  Google Scholar 

  22. United States Pharmacopeia 29 (2005), <905> Uniformity of Dosage Units.

  23. Fernando GT, Glenn A, Meyer MA, Ricci MA, Coppari A C, Gustavo A, Triple combination release multi-layered tablet, United States Patent 244473,2005.

  24. Zhang Y, Law Y, Chakrabarti S. Physical properties and compact analysis of commonly used direct compression binders. AAPS Pharma Sci Tech 2003;4(4) Article 62.

  25. Okor RS, Uhumwangho MU, Adogah JT. Potential of carnauba wax in ameliorating brittle fracture during tableting. Pack J Pharm Sci. 2009;22(1):58–61.

    Google Scholar 

  26. Basak SC, Kumar KS, Ramalingam M. Design, and release characteristics of sustained release tablet containing metformin HCl. Brazilian J Pharm Sci. 2008;44(3):477–83.

    CAS  Google Scholar 

  27. Saber M, Magnard F, Bouzon J, Vergnaud JM. Modeling of matter transfers in drug-polymer device used as galenic form. J Polym Eng. 1988;8:295–314.

    Article  CAS  Google Scholar 

  28. Stamm A, Tritsch JC. Some consideration on the liberation of drugs from inert matrices. Drug Dev Ind Pharm. 1989;12:2337–53.

    Article  Google Scholar 

  29. Talukder M, Shafiqur R, Tasnuva H. Statistical evaluation of hydrophobic polymer-based diclofenac sodium matrix tablet. Der Pharma Chemica. 2009;1(1):225–37.

    CAS  Google Scholar 

  30. Guyot M, Fawaz F. Nifedipine loaded polymeric microsphere: preparation and physical characteristics. Int J Pharm. 1998;175:61–74.

    Article  CAS  Google Scholar 

  31. Kibbe AH. Handbook of Pharmaceutical excipients. Washington, DC, USA: American Pharmaceutical Association 2000.

  32. Boza A, Caraballo I, Alvarez-Fuentes J, Rabasco AM. Evaluation of Eudragit RSPO and Ethocel 100 matrices for the controlled release of lobenzarit disodium. Drug Dev Ind Pharm. 1999;25(2):229–33.

    Article  CAS  PubMed  Google Scholar 

  33. Lee PI. Diffusional release of a solute from polymeric matrix-approximate analytical solutions. J Memb Sci. 1980;7:255–75.

    Article  CAS  Google Scholar 

  34. Indranil KY, Hari PS, Rana PS, Dinesh C, Durga J, Jain DA, et al. Formulation and optimization of aceclofenac sustained release matrix tablets. Int J Pharm Tech. 2010;2(1):592–8.

    Google Scholar 

  35. Emami J, Tajeddin, Ahmadi F. Preparation and in vitro evaluation of sustained release matrix tablets of flutamide using synthetic and naturally occurring polymers. Iranian J Pharma Res 2008;7(4):247–256.

  36. Swain RP, Kumari TR, Panda S. Formulation development and evaluation of sustained release ibuprofen tablets with acrylic polymers (Eudragit) and HPMC. Int J Pharm Pharm Sci; 8(2):131–5.

  37. Katikaneni PR, Upadrashta SM, Neau SH, Mitra AK. Ethylcellulose matrix-controlled release tablets of water-soluble drug. Int J Pharm. 1995;123(1):119–25.

    Article  CAS  Google Scholar 

  38. Hazneder S, Dortunc B. Preparation, and in vitro evaluation of Eudragit microspheres containing acetazolamide. Int J Pharm. 2004;269(1):131–40.

    Article  Google Scholar 

  39. Apu AS, Pathan AH, Shrestha D, Kibria G, Jalil R. Investigation of in vitro release kinetics of carbamazepine from Eudragit® RSPO and RLPO matrix tablets. Tropical J Pharm Res. 2009;8(2):145–52.

    Article  CAS  Google Scholar 

  40. Sasidhar RLC, Vidyadhara S, Ramesh J, Nagaraju R, Prakash K. Formulation and evaluation of controlled release of losartan potassium matrix tablets using poly (ethyleneoxides). Curr Trends Biotechnol Pharm 2009;3(4): 440–446.

  41. Skinner GW, Harcum WW, Durig T. Ethylcellulose in direct compression modified release tablets: impact of polymer structure and formulation variables. HERCULES: Aqualon Davison 2002;PTR-023.

  42. Sinah VR, Agrawal MK, Kumria R. Influence of formulation and excipient variables on the pellet properties prepared by extrusion spheronization. Curr Drug Deliv. 2005;2(1):1–8.

    Article  Google Scholar 

  43. Bastos O, Friedrich B, Beck R. Effects of filler-binders and lubricants on physicochemical properties of tablets obtained by direct compression: A22 factorial design. Lat Am J Pharm. 2008;27(4):578–83.

    CAS  Google Scholar 

  44. Rahman SMH, Telny TC, Ravi TK, Kuppusamy S. Role of surfactant, and pH in dissolution of curcumin. Ind J Pharm Sci. 2009;71(2):139–42.

    Article  CAS  Google Scholar 

  45. Huang Y, Wu P, Chang J, Tsai M, Tsai Y. Design, and evaluation of sustained release microsphere of potassium chloride prepared by Eudragit. Eur J Pharm Sci. 2003;19(2–3):115–22.

    PubMed  Google Scholar 

  46. Pamudji JS, Sjuib F, Ibrahim S, Sumirtapura Y. Study on release of dextromethorphan hydrobromide from tablet matrix of Eudragit RSPO into media of different pH. Acta Pharm Indon. 2005;30(3):89–93.

    Google Scholar 

  47. Moore J, Flanner H. Mathematical comparison of dissolution profiles. Pharm Tech. 1996;20(6):64–74.

    Google Scholar 

  48. Apurba SA, Atiqul HP, Golam K, Rezaul J. In vitro release kinetic study of theophylline from Eudragit RSPO and Eudragit RLPO matrix tablets. J Pharm Sci. 2009;8(1):1–6.

    Google Scholar 

  49. Silversteine R, Webster F, Kiemel D. Infrared spectrometry in spectrometric identification of organic compounds. 7th ed. John Wily and Sons: Inc; 2005. p. 72–126.

    Google Scholar 

  50. Patrick S. Chemical kinetics and stability in Martin’s physical pharmacy and pharmaceutical sciences. 5th ed. USA: Lippincott Williams and Wilkins; 2006. p:411.

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, College of Pharmacy, Knowledge University, Erbil, Iraq

    Muath Sheet Mohammed Ameen

  2. Department of Pharmaceutics, College of Pharmacy, Hawler Medical University, Erbil, Iraq

    Naz Jamal Ibrahim

  3. College of Pharmacy, University of Mosul, Mosul, Iraq

    Thamer A. Omar

  4. Chemical and Biochemical Engineering, Rutgers University, 98 Brett Road, Piscataway, NJ, 08854, USA

    Thamer A. Omar

Authors
  1. Muath Sheet Mohammed Ameen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naz Jamal Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thamer A. Omar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Muath Sheet Mohammed Ameen.

Ethics declarations

Competing Interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ameen, M.S.M., Ibrahim, N.J. & Omar, T.A. Design and Evaluation of Sustained Release Bilayer Tablets of Oxcarbazepine. J Pharm Innov 18, 1213–1228 (2023). https://doi.org/10.1007/s12247-022-09694-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12247-022-09694-2

Keywords

Search

Navigation